open access

Vol 10, Supp. A (2019)
Case report
Published online: 2019-04-26
Get Citation

The effectiveness of ruxolitinib in a patient with primary myelofibrosis

Agata Obara1, Marcin Pasiarski1
DOI: 10.5603/Hem.2019.0010
Affiliations
  1. Klinika Hematologii i Transplantacji Szpiku, Świętokrzyskie Centrum Onkologii, ul. Artwińskiego 3, 25–734 Kielce, Poland

open access

Vol 10, Supp. A (2019)
CASE REPORTS
Published online: 2019-04-26

Abstract

Primary myelofibrosis belongs to chronic myeloproliferative neoplasms BCR-ABL1-negative. In this article, we present a case of 74 years-old woman, treated with hydroxyurea at the beginning of the diagnosis. Subsequently, ruxolitinib therapy was started.

Abstract

Primary myelofibrosis belongs to chronic myeloproliferative neoplasms BCR-ABL1-negative. In this article, we present a case of 74 years-old woman, treated with hydroxyurea at the beginning of the diagnosis. Subsequently, ruxolitinib therapy was started.

Get Citation

Keywords

primary myelofibrosis, hydroxyurea, ruxolitinib

About this article
Title

The effectiveness of ruxolitinib in a patient with primary myelofibrosis

Journal

Hematology in Clinical Practice

Issue

Vol 10, Supp. A (2019)

Article type

Case report

Pages

13-14

Published online

2019-04-26

DOI

10.5603/Hem.2019.0010

Keywords

primary myelofibrosis
hydroxyurea
ruxolitinib

Authors

Agata Obara
Marcin Pasiarski

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.